Evidence map›Paper›PMID 40733046›Full record

ArticlePharmaceutics2025

PET and SPECT Tracer Development via Copper-Mediated Radiohalogenation of Divergent and Stable Aryl-Boronic Esters.

Austin Craig, Frederik J Sachse, Markus Laube, Florian Brandt, Klaus Kopka, Sven Stadlbauer

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A simplified, robust protocol for [Scientific reports · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Austin CraigInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.ORCID 0000-0001-7721-5278
Frederik J SachseInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.ORCID 0009-0002-6790-9502
Markus LaubeInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.ORCID 0000-0003-4916-3794
Florian BrandtUniversitätsklinikum Carl Gustav Carus Dresden, Fetscherstraße 74, D-01307 Dresden, Germany.ORCID 0000-0001-7711-4805
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.ORCID 0000-0003-4846-1271
Sven StadlbauerInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, D-01328 Dresden, Germany.ORCID 0000-0003-2276-5330

Funding

Helmholtz Enterprise funding (associated with Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V.) HE-2023-08
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

123I-iodination18F-fluorinationcopper-mediated radiohalogenation (CMRH)positron emission tomography (PET)prosthetic groupradiohalogenationsingle-photon emission computed tomography (SPECT)

Identifiers

PMID40733046
PMCPMC12298831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.